Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • Contact

When medical research turns personal

    Home News When medical research turns personal
    NextPrevious

    When medical research turns personal

    By sarah | News | 0 comment | 4 September, 2019 | 0

    By Scott Meacham
    Copyright © 2019, The Oklahoman

    Of the more than 120 types of brain and central nervous system tumors, Glioblastoma (also called GBM) is the most aggressive — a deadly brain cancer with no cure.

    Glioblastomas often appear with no warning or prior symptoms. These Type IV tumors tend to produce their own blood vessels and are highly malignant. The cells spread fast and send tentacles to other parts of the brain, which makes complete surgical removal virtually impossible.

    The typical prognosis is 12 to 18 months. In the U.S., about 12,000 people are diagnosed with glioblastoma each year. Recently, my mother, who is nearly 80 but an otherwise very healthy and active woman, became one of those 12,000.

    This is a hard column for me to write as I face the loss of a constant source of love and support throughout my life, but my mother’s attitude — she is a woman of faith and takes each day as it comes —  drove home to me, in a very personal way, the importance of the work that we do in life science.

    The impact of state-funded research, spinning out new technologies, and supporting innovators and entrepreneurs goes far, far beyond patents, job creation, and risk adjusted rates of return.

    As Sherri Wise, Osteopathic Founders Foundation President/CEO and chair of the Oklahoma Center for the Advancement of Science & Technology (OCAST) Seed Capital Investment Committee, often reminds us at committee meetings, “Let’s not lose sight of the fact that we are saving lives and helping people.”

    Last fall, as a commercialization partner with the Oklahoma Medical Research Foundation (OMRF), our two organizations worked together to create a novel investment framework to manage a breakthrough drug therapy for glioblastoma. (I had no idea at the time that my family would be affected by this terrible disease.)

    Oblato, Inc., the U.S.-based subsidiary of a Korea investment firm that focuses on rare disease indications, purchased all rights to OKN-007, an investigational drug for GBM that had been in clinical testing with patents at the University of Oklahoma’s Stephenson Cancer Center. Oblato will initiate additional trials in larger populations and has plans to develop an oral form of the drug, which is now administered as an infusion.

    This project is noteworthy as, to my knowledge, it is the first of its kind in Oklahoma where a not-for-profit research institution without clinical infrastructure collaborated under a novel investment structure to manage a new drug therapy through clinical trials, delivering results that generate a commercial collaboration.

    OKN-007 won’t change my mother’s situation. But quite possibly someday, we will look back and know that the research funding from OCAST, the seed funding from i2E’s Oklahoma Seed Capital Fund, and the creativity and flexibility of OMRF to champion a seamless collaboration between multiple institutions, did result in a treatment for glioblastoma that might help someone else’s mom.

    The human side is the real reason that Oklahoma’s investment in life sciences matters. Therapeutics and diagnostics that improve people’s lives is the real reason we do what we do.

    Scott Meacham is president and CEO of i2E Inc., a nonprofit corporation that mentors many of the state’s technology-based startup companies. i2E receives state appropriations from the Oklahoma Center for the Advancement of Science and Technology. Contact Meacham at i2E_Comments@i2E.org.

    glioblastoma, Oblato, OCAST, Oklahoma Medical Research Foundation, Oklahoma Seed Capital Fund, OMRF, Scott Meacham

    Related Post

    • There’s no single path to entrepreneurial success

      By sarah | Comments are Closed

      By Scott Meacham There is no single path to entrepreneurial success. U.S. Patent No. 4,371,752 is just one of the more than thirty-three patents issued to Tulsa born and raised inventor and entrepreneur Gordon MatthewsRead more

    • Nautilus inventor created source of wealth and jobs

      By sarah | Comments are Closed

      By Scott Meacham The inventor of the Nautilus exercise machines created a source of wealth and jobs. Arthur A Jones, the inventor of Nautilus exercise machines, grew up in Seminole, OK. His father practiced medicine.Read more

    • Charles Machine Works a case study in entrepreneurship

      By sarah | Comments are Closed

      By Scott Meacham Charles Machine Works is a case study in entrepreneurship and innovation. To succeed in entrepreneurship, solve a problem that lots of businesses have. You can be even more successful, if the businessRead more

    • A real life success story in Ed Roberts and the Altair 8800

      By sarah | Comments are Closed

      By Scott Meacham Oklahoma State University alumni Ed Roberts is a real life success story with the invention of the Altair 8800 personal computer. About a third of i2E’s clients are in software/IT businesses. WeRead more

    • iMCI leads $750,000 investment in OKC-based PrivacyBrain

      By sarah | Comments are Closed

      Back to Newsletter March 17, 2021 Contact: Sarah Seagraves, Senior VP for Marketing sseagraves@i2E.org OKLAHOMA CITY — i2E Management Co., Inc., (iMCI) recently led a $750,000 seed-round investment in Oklahoma City-based PrivacyBrain. PrivacyBrain is aRead more

    Leave a Comment

    Cancel reply

    You must be logged in to post a comment.

    NextPrevious
    i2E-300dpi-Trans-Light
    • Events
    • News
    • Resources
    • Library
    • Love’s Cup

    Oklahoma City Office

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305
    Click HERE for printable map with directions.

    Tulsa Office

    618 E. Third Street, Suite 1
    Tulsa, OK 74120
    PHONE 918/582-5592
    Click HERE for printable map with directions.
    Copyright 2021 i2E, Inc. | All Rights Reserved
    • #withOklahomaStartups
    • #withOklahomaStartups
    • #withOklahomaStartups- copy
    • 2016 BrewFest
    • 2018 Paulsen Award Application
    • 2019 Business Plan Submittal Form
    • 2019 Intent to Compete
    • 2019 Oral Competition Submittal Form
    • 2019 Paulsen Award Application
    • 2020 Business Plan Submittal Form
    • 2020 Oral Competition Submittal Form
    • 2020 Paulsen Award Application
    • 2021 Official Application Form
    • 2021 Oral Competition Submittal Form
    • 2021 Paulsen Award Application
    • 4DSales
    • About
    • About i2E
    • About Us
    • ACT Tulsa
    • Add Listing
    • Alkami
    • Biolytx
    • BP Endo
    • Clear River Enviro
    • Concept Fund
    • Contact
    • COVID-19 News from i2E
    • COVID19 Resources for Scalable Startups
    • CreditPoint
    • Datebox
    • DermaMedics
    • DEX Pump
    • DigitalSix
    • Directory
    • Directory Dashboard
    • Docvia
    • Driven Analytics
    • e3
    • e3 Goes Virtual
    • e3: #withOklahomaStartups
    • Entrepreneurial Development
    • Entrepreneurial Summit
    • Entrepreneurial Summit Speakers
    • Entrepreneurs-in-Residence
    • Entrepreneurship
    • Events
    • Events
    • Exaptive
    • Exerbotics
    • Expert TA
    • Founder’s Book Nook
    • Home
    • Home
    • i2E Directory
    • i2E Events
    • iMCI
    • iMCI Investment Funds
    • Investments
    • iRecommend
    • Kirrhos
    • Letter from iMCI’s Executive in Residence in a time of great uncertainty
    • Library
    • Lifetone
    • Linear Health Sciences
    • Love’s Cup
      • Forms
      • High Growth
      • Paulsen Awards
      • Small Business
      • Timeline
    • Love’s Cup is Unstoppable
    • Love’s Cup W-9
    • MaxQ
    • Moleculera Labs
    • Monscierge
    • MS Pen Technologies
    • My Account
    • News
    • Newsletter
    • Newsletter Archive
    • OKBio
    • OKBio Directory
    • OMRF Glioblastoma
    • Otologics Pharmaceuticals
    • Past Winners
    • PhotoniCare
    • PolySkope Labs
    • Portfolio
    • Portfolio 3
    • Private Partners Opportunity Fund
    • Progentec Diagnostics
    • Q&A with Kevin Moore
    • Q&A with Michael Basch
    • Quarterly Report
    • Raw Space for Rent
    • Resources
    • Roll to Roll Technologies
    • Selexys Pharmaceuticals
    • Send a Ride
    • Simergent
    • Spiers New Technologies
    • Synercon Technologies
    • Tailwind
    • Ten Nine Technologies
    • Testimonials
    • Tetherex Pharmaceuticals
    • The Greg Main Distinguished Scholar Award
    • THG Energy Solutions
    • Thoughts from local business leaders and startup founders on the effects of COVID on their industry
    • Thoughts Post Shut In
    • Tulsa Collab: COVID-19 Efforts & Resources for Entrepreneurs
    • Tulsa GEW
    • Valve Systems International
    • Venture Advisory Services
    • Video
    • Virtuoso
    • Webmail Test Page
    • WeGoLook
    • Well Checked Systems
    • Whiteboard CRM
    i2E